# US 2024/0197637 A1 · Polymeric microparticles for the local treatment of chronic inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197637 A1
- Document ID: US20240197637A1
- Status: Published application
- Kind: A1
- Application number: 18/287,093
- Filed: 2022-04-13
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: Fondazione Istituto Italiano Di Tecnologia; The University of North Carolina at Chapel Hill
- Applicants: Fondazione Istituto Italiano Di Tecnologia; The University of North Carolina at Chapel Hill
- Inventors: Paolo DECUZZI; Martina DI FRANCESCO; Lara LONGOBARDI; Huseyin OZKAN
- Web page: https://patentgrep.com/patent/US20240197637A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to drug-delivery compositions comprising microparticles with the shape of a prism comprising at least one polymer and at least one CCR2 inhibitor. Preferably said composition is for the treatment of local chronic inflammation diseases, such as osteoarthritis.

## Claims

### Claim at position 1

1: A drug-delivery composition comprising one or more microparticles, wherein each microparticle has a shape of a prism with three or more sides, and each side has a side length comprised between about 5 and about 50 μm and a height length comprised between about 5 and about 50 μm, said microparticle comprising at least one polymer and at least one inhibitor of C-C Chemokine Receptor-2 (CCR2).

### Claim at position 2 (depends on 1)

2: The drug-delivery composition according to claim 1 wherein said microparticle has the shape of a prism with a square base.

### Claim at position 3 (depends on 2)

3: The drug-delivery composition according to claim 2 wherein the side length is of about 20 μm and the height length is of about 10 μm.

### Claim at position 4 (depends on 1)

4: The drug-delivery composition of claim 1, wherein said microparticle has a Young's modulus under compression comprised between 1 KPa and 10 MPa, preferably from 100 KPa to 10 MPa.

### Claim at position 5 (depends on 1)

5: The drug-delivery composition of claim 1, wherein said polymer is selected from the group consisting of poly(lactic-co-glycolic acid)(PLGA), polyethylene glycol (PEG), polycaprolactone (PCL), hyaluronic acid (HA), chitosan, gelatin and a combination thereof.

### Claim at position 6 (depends on 1)

6: The drug-delivery composition of claim 1, wherein said CCR2 inhibitor is selected from the group consisting of RS504393, Maraviroc, cenicriviroc, CD192, CCX872, CCX140, 2-((Isopropylaminocarbonyl)amino)-N-(2-((cis-2-((4(methylthio)benzoyl)amino)cyclohexyl)amino)-2-oxoethyl)-5-(trifluoromethyl)-benzamide, vicriviroc, SCH351125, TAK779 and CCR2 antagonist 4.

### Claim at position 7 (depends on 1)

7: The drug-delivery composition of claim 1, wherein said CCR2 inhibitor is loaded on a nanoparticle.

### Claim at position 8 (depends on 1)

8: The drug-delivery composition of claim 1, wherein each microparticle comprises poly(lactic-co-glycolic acid)(PLGA) and RS504393.

### Claim at position 9 (depends on 1)

9: The drug-delivery composition of claim 1, wherein said microparticle further comprises an anti-inflammatory drug, or dexamethasone.

### Claim at position 10 (depends on 1)

10: The drug-delivery composition of claim 1, wherein said microparticle further comprises a drug selected from the group consisting of: glucocorticoids; non-steroidal anti-inflammatory drugs; monoclonal antibody against the tumor necrosis factor-alpha (TNF-α), certolizumab pegol; TNF-α inhibitors, Golimumab; antiplatelet drugs, Tirofiban; kinase inhibitors, such as Ruxolitinib; CLK/DYRK1A inhibitors, Lorecivivint; and Fetuin A.

### Claim at position 11 (depends on 1)

11: The drug-delivery composition of claim 1, wherein said microparticle further comprises one or more nanoparticles, lipidic and polymeric nanoparticles or short interfering RNA (siRNA)-loaded nanoparticles.

### Claim at position 12 (depends on 1)

12: The drug-delivery composition of claim 1, for use as a medicament.

### Claim at position 13 (depends on 1)

13: A method for treating or preventing a localized chronic inflammation disease comprising administering to an individual in need thereof a drug-delivery composition of claim 1.

### Claim at position 14 (depends on 13)

14: The method of claim 13, wherein said localized chronic inflammation disease is osteoarthritis.

### Claim at position 15 (depends on 13)

15: The method of claim 13 wherein said composition is administered by intra-articular injection.

### Claim at position 16 (depends on 1)

16: A pharmaceutical composition comprising: the drug delivery composition of claim 1, and (b) a pharmaceutically acceptable excipient and/or a carrier.

### Claim at position 17

17: A drug-delivery composition comprising one or more microparticles, wherein each microparticle has non-spherical shape, and each microparticle is between about 1 and 100 μm in size, and said microparticle comprises at least one polymer and at least one inhibitor of C-C Chemokine Receptor-2 (CCR2).

### Claim at position 18 (depends on 17)

18: The drug-delivery composition of claim 17, wherein each microparticle is in the shape of a prism.

### Claim at position 19 (depends on 17)

19: The drug-delivery composition of claim 17, wherein the prism is a polyhedron comprising a first n-sided polygonal base, a second base which is a translated copy that is rigidly moved without rotation, and n other faces joining corresponding sides of the two bases, and the n other faces are parallelograms, wherein n is the number of sides of the polyhedron.

### Claim at position 20 (depends on 19)

20: The drug-delivery composition of claim 19, wherein n is between about 3 and 8, or is 4.
